Leadless pacemaker implementation at the right atrial appendage apex: An initial preclinical assessment

Objective This study evaluates the feasibility and efficacy of implanting a leadless pacemaker at the right atrial appendage (RAA) in a preclinical minipig model, aiming to address the limitations of atrial pacing with current leadless devices like the Medtronic Micra, which is typically used for ri...

Full description

Saved in:
Bibliographic Details
Published inPacing and clinical electrophysiology Vol. 47; no. 8; pp. 1124 - 1127
Main Authors Lin, Yu‐Sheng, Wu, Lung‐Sheng, Ho, Wan‐Chun, Lai, Chao‐Sung, Su, Wilber, Chu, Pao‐Hsien
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.08.2024
Subjects
Online AccessGet full text
ISSN0147-8389
1540-8159
1540-8159
DOI10.1111/pace.15003

Cover

More Information
Summary:Objective This study evaluates the feasibility and efficacy of implanting a leadless pacemaker at the right atrial appendage (RAA) in a preclinical minipig model, aiming to address the limitations of atrial pacing with current leadless devices like the Medtronic Micra, which is typically used for right ventricular implantation. Methods Four minipigs, each with a median body weight of 45.8 ± 10.0 kg, underwent placement of the Micra transcatheter pacing system (TPS) via the right femoral vein into the RAA apex. The pacing performance was assessed over 1‐week (short‐term) and 3‐month (long‐term) periods. Outcomes The initial findings indicated successful implantation, with satisfactory intrinsic R‐wave amplitudes and pacing threshold. In the following period, the sensitivity, threshold, and impedance were stable with time. Notably, upon explanation at 3 months, a deep myocardial penetration by the device was observed, necessitating a redesign for safe long‐term use in a growing subject's heart. Conclusion While initial results suggest that RAA apex placement of the Micra TPS is promising for potential inclusion in a dual‐chamber pacing system, the issue of myocardial penetration highlights the need for device redesign to ensure safety and effectiveness in long‐term applications.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0147-8389
1540-8159
1540-8159
DOI:10.1111/pace.15003